Preclinical Data On The Biodistribution Presented By Stoke Therapeutics

Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome. Stoke Therapeutics, Inc., a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today presented new preclinical data on STK-001, a potential new disease-modifying medicine for the treatment of Dravet syndrome.

Link:
businesswire.com/news/home/20191208005025/en/Stoke-Therapeutics-Presents-Preclinical-Data-Biodistribution-Target